Is The Time Finally Right For Bispecific Antibodies?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck, Lilly, Gilead and Celgene are among the companies striking deals that involve bispecific antibodies. The novel dual-acting drugs have been in development since the 1980s with little success, yet big pharma believes they may finally be coming of age.